Category

News
This story was originally published on The Limbic  Improving the outcomes of multiple myeloma patients with high-risk abnormalities (HRA) continues to pose a therapeutic challenge, but the future of multiple myeloma treatment is bright, with so many active drugs and immunotherapies on the horizon, a recent Amgen-sponsored educational meeting in Perth heard. Doctor M Hasib...
Continue Reading
Go along in person or watch live on Facebook (see details below) as Pharmac presents their oral submission at the Committee’s meeting on Wednesday, 23 October 2019, from approximately 08.30am to 09.50am, at Parliament Buildings in Wellington. They will address all of the following petitions in one submission. Petition of Jeffrey Chan: Ask Pharmac to...
Continue Reading
This story was originally published on stuff Every three months, a package containing cancer medication arrives at Trevor Gately’s Nelson home from India. The 73-year-old was diagnosed with multiple myeloma in 2016. A form of blood cancer, it causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells. After...
Continue Reading
OPINION: Statements about priorities for the new cancer agency made by agency head Professor Diana Sarfati are cause for serious concern. Last Saturday’s profile of Sarfati, in which she was asked to name her three priorities, said: “One thing not on that priority wish list is more money for the stream of high-cost, life-prolonging drugs for terminal cancer,...
Continue Reading
Greetings A lot has happened since my last newsletter, but hopefully you’ve been keeping up with some of this through our website. The big event of the year has been the launch of our new Myeloma Burden of Disease report at a breakfast in Parliament on 26 June. Read about it here.  This three-part suite...
Continue Reading
Myeloma UK funded research from The Institute of Cancer Research, London, has identified the main biological processes which cause the genetic mutations associated with the development of myeloma. The research, published in Blood Cancer Journal, increases our knowledge of how myeloma develops and evolves and also suggests that analysis of mutational signatures could play a role...
Continue Reading
A retrospective cohort study identified real-world epidemiology, treatment patterns, and survival outcomes in patients with multiple myeloma (MM) in Israel. The findings were reported in Leukemia Research. The study was conducted using databases from Maccabi Healthcare Services, a nationwide health plan in Israel that accounts for a quarter of the country’s population. The prevalence of MM was determined...
Continue Reading
Blood cancer is actually a term applied to three different types of cancer – leukemia, lymphoma and myeloma. For centuries, these cancers had virtually no possibility of survival. Even as recently as the 1960s, the five-year survival rate for leukemia was 14%. By 2010, it had increased to 61%. Similar gains have been made in the survival...
Continue Reading
Patients with multiple myeloma are at risk of developing thrombosis (blood clots) that are associated with some newer treatments, according to two myeloma experts. Therefore, researchers from Fred Hutchinson Cancer Research Center, the University of Washington and Seattle Cancer Alliance, examined if they could identify risk factors for patients to determine who would most likely...
Continue Reading
1 2 3 4 20

Floor 7, 90 The Terrace
Wellington Central
New Zealand